What Patient-Reported Outcomes Show for Wegovy
Patient-reported outcomes (PROs) for Wegovy (semaglutide 2.4 mg), used for chronic weight management, come mainly from Novo Nordisk's STEP clinical trials. These measure health-related quality of life via the SF-36v2 survey, which tracks physical functioning, bodily pain, general health, vitality, social functioning, emotional well-being, mental health, and mental component summary (MCS) scores. Patients on Wegovy reported larger improvements than placebo groups, especially in physical domains, starting at week 20 and sustained through 68 weeks.[1][2]
In STEP 1 (obese adults without diabetes), Wegovy users gained 6.3 more points on physical component summary (PCS) scores versus placebo (difference: 95% CI 4.8-7.9; p<0.0001). Vitality improved by 5.1 points more (95% CI 3.3-6.9).[1]
STEP 2 (type 2 diabetes patients) showed 4.2-point PCS gain (95% CI 2.4-6.0; p<0.0001) and 3.7-point vitality gain (95% CI 1.6-5.8).[2]
How Weight Loss Ties to Quality-of-Life Gains
PRO improvements correlated with weight loss magnitude. Patients losing ≥20% body weight saw bigger SF-36 gains (PCS difference: 8.0 points vs. placebo). Obesity-related issues like joint pain and fatigue drove early gains, with mental health benefits emerging later.[3]
A 2-year extension of STEP 1 confirmed sustained PCS improvements (mean +7.2 points at week 104).[4]
Common Patient Concerns from Real-World Reports
Beyond trials, patient forums and post-marketing data highlight nausea (44% in trials), diarrhea, and vomiting as initial hurdles, often resolving after 20 weeks. Some report better mood and energy long-term, but others note "Ozempic face" (facial sagging from fat loss) or muscle loss affecting physical function. Sexual function PROs were not primary endpoints but indirectly improved via weight-related confidence.[5][6]
How Wegovy PROs Compare to Other Weight Loss Drugs
Wegovy outperforms liraglutide (Saxenda) on SF-36 PCS (5.0 vs. 1.8 points at 68 weeks) and rivals tirzepatide (Zepbound), which showed similar PCS gains (around 6 points) but stronger weight loss in head-to-head data.[7][8]
| Drug | Mean Weight Loss (68 weeks) | SF-36 PCS Gain vs. Placebo |
|------|-----------------------------|----------------------------|
| Wegovy | -15% to -18% | +4 to +6 points |
| Zepbound | -20% to -21% | +5 to +7 points |
| Saxenda | -8% to -12% | +1 to +3 points |
Factors Affecting Individual PROs
Women and older patients (>65) reported higher baseline impairments but similar relative gains. Comorbidities like depression amplified mental health benefits. GI side effects reduced short-term PROs in 10-15% of users, leading to 7% discontinuation.[1][9]
No Wegovy-specific patents directly cover PRO data; semaglutide formulation patents expire 2032 in the US.[10]
[1]: NEJM, STEP 1 trial (2021). https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[2]: Lancet, STEP 2 trial (2021). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00858-0/fulltext
[3]: Wilding et al., Diabetes Obes Metab (2021).
[4]: Garvey et al., NEJM (2022).
[5]: FDA Wegovy label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
[6]: Patient reviews on Drugs.com (aggregated).
[7]: Pi-Sunyer et al., NEJM Saxenda trial (2015).
[8]: Jastreboff et al., NEJM SURMOUNT-1 (2022).
[9]: Rubino et al., JAMA (2021).
[10]: DrugPatentWatch.com. https://www.drugpatentwatch.com/p/tradename/WEGOVY